EA201891575A1 - Составы для лечения рака мочевого пузыря - Google Patents
Составы для лечения рака мочевого пузыряInfo
- Publication number
- EA201891575A1 EA201891575A1 EA201891575A EA201891575A EA201891575A1 EA 201891575 A1 EA201891575 A1 EA 201891575A1 EA 201891575 A EA201891575 A EA 201891575A EA 201891575 A EA201891575 A EA 201891575A EA 201891575 A1 EA201891575 A1 EA 201891575A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- formulations
- compositions
- treatment
- proliposomal
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002485 urinary effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 5
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 abstract 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- AMCPECLBZPXAPB-UHFFFAOYSA-N propane-1,2,3-triol;sodium Chemical compound [Na].OCC(O)CO AMCPECLBZPXAPB-UHFFFAOYSA-N 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
- 208000023747 urothelial carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Настоящее изобретение относится к композициям и способам для получения и применения пролипосомных и липосомных составов химиотерапевтических средств. Пролипосомные и липосомные составы химиотерапевтических средств, а также лекарственные средства и лекарственные формы, включающие такие составы, можно использовать со схемами лечения рака мочевого пузыря и уротелиальной карциномы. Таким образом, составы, лекарственные средства и лекарственные формы по изобретению подходят для лечения рака мочевого пузыря посредством внутрипузырного введения и для лечения уротелиальной карциномы. Составы по изобретению включают (a) таксан (например, паклитаксел, доцетаксел) или цисплатин, (b) первый фосфолипид, дипальмитоилфосфатидилхолин (DMPC), и (c) второй фосфолипид, димиристилфосфатидилглицерин натрия (DMPG). Пролипосомные составы образуют липосомы после контакта с водным средством.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275936P | 2016-01-07 | 2016-01-07 | |
| US201662275941P | 2016-01-07 | 2016-01-07 | |
| US201662421137P | 2016-11-11 | 2016-11-11 | |
| PCT/US2017/012720 WO2017120586A1 (en) | 2016-01-07 | 2017-01-09 | Formulations for treating bladder cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201891575A1 true EA201891575A1 (ru) | 2019-01-31 |
| EA038653B1 EA038653B1 (ru) | 2021-09-29 |
Family
ID=59274569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891575A EA038653B1 (ru) | 2016-01-07 | 2017-01-09 | Составы для лечения рака мочевого пузыря |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11229602B2 (ru) |
| EP (1) | EP3400072B1 (ru) |
| JP (3) | JP6697541B2 (ru) |
| KR (1) | KR20180103039A (ru) |
| CN (2) | CN108136217B (ru) |
| AU (1) | AU2017205337B2 (ru) |
| BR (1) | BR112018013896A2 (ru) |
| CA (1) | CA3009809A1 (ru) |
| CL (1) | CL2018001838A1 (ru) |
| CO (1) | CO2018007674A2 (ru) |
| CR (1) | CR20180388A (ru) |
| DK (1) | DK3400072T3 (ru) |
| EA (1) | EA038653B1 (ru) |
| ES (1) | ES2863659T3 (ru) |
| HK (1) | HK1255212A1 (ru) |
| IL (1) | IL260346B2 (ru) |
| MX (2) | MX2018008267A (ru) |
| MY (1) | MY198105A (ru) |
| PE (1) | PE20181445A1 (ru) |
| PH (1) | PH12018501451A1 (ru) |
| SG (1) | SG11201805594PA (ru) |
| WO (1) | WO2017120586A1 (ru) |
| ZA (1) | ZA201804968B (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018047074A1 (en) * | 2016-09-07 | 2018-03-15 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
| MX2019005185A (es) | 2016-11-11 | 2019-07-01 | Univ Western Health Sciences | Metodos para tratar las carcinomas uroteliales del tracto superior. |
| WO2018169960A1 (en) * | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Nanoparticle formulations for enhanced drug delivery to the bladder |
| LU101155B1 (en) * | 2017-07-19 | 2019-04-25 | Tesorx Pharma Llc | Liposomal Paclitaxel Formulation for Treating Bladder Cancer |
| CA3138484A1 (en) * | 2018-05-04 | 2019-11-07 | Lipac Oncology Llc | Balloon catheter |
| WO2020093044A1 (en) * | 2018-11-02 | 2020-05-07 | Tesorx Pharma, Llc | Liposomal enhanced intra-peritoneal chemotherapy |
| GB201900389D0 (en) | 2019-01-11 | 2019-02-27 | Queens Univ Of Belfast | Solvent and water-free lipid-based nanoparticles and their methods of manufacture |
| CN113189315B (zh) * | 2021-04-13 | 2024-01-23 | 山东省医疗器械产品质量检验中心 | 评价抗菌导尿管抗菌活性的体外动态模型及其使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1330938C (en) | 1985-10-18 | 1994-07-26 | Abdul R. Khokhar | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
| US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| US5902604A (en) * | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| ES2272496T3 (es) * | 2000-02-04 | 2007-05-01 | Lipoxen Technologies Limited | Procedimiento de deshidratacion/rehidritacion para la preparacion de lipososmas. |
| US8658202B2 (en) * | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| US7238367B2 (en) * | 2001-10-03 | 2007-07-03 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| EP1596825A2 (en) | 2003-02-03 | 2005-11-23 | Neopharm, Inc. | Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs |
| JP4786538B2 (ja) * | 2003-10-01 | 2011-10-05 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 親油性薬物送達ビヒクルおよびその使用方法 |
| WO2005072776A2 (en) * | 2004-01-30 | 2005-08-11 | Instytut Farmaceutyczny | Liposomal formulations of the antineoplastic agents |
| EP1778217A4 (en) * | 2004-07-28 | 2008-10-08 | Sd Pharmaceuticals Inc | STABLE INJECTABLE COMPOSITION OF ALPHA-TOCOPHERYLSUCCINATE; ANALOGUE AND SALTS FROM IT " |
| US8709379B2 (en) | 2006-03-29 | 2014-04-29 | Scitech Development, Llc | Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery |
| EP2076244B1 (en) | 2006-10-10 | 2016-12-07 | Jina Pharmaceuticals Inc. | Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof |
| CN101322689B (zh) * | 2007-06-11 | 2012-10-24 | 江苏先声药物研究有限公司 | 一种多西他赛长循环脂质体及其冻干粉针的制备方法 |
| WO2010009186A1 (en) * | 2008-07-15 | 2010-01-21 | The Board Of Trustees Of The University Of Illinois | Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| US20110166214A1 (en) * | 2010-01-07 | 2011-07-07 | Innopharma, Llc | Methods and compositions for delivery of taxanes in stable oil-in-water emulsions |
| EA201791738A1 (ru) * | 2012-05-09 | 2018-03-30 | Вестерн Юниверсити Оф Хелт Сайенсиз | Пролипосомальные композиции тестостерона |
| CN103570766B (zh) * | 2012-08-09 | 2016-04-13 | 浙江海昶生物医药技术有限公司 | 一种新型铂类脂质体制剂及其制备方法 |
| CN103768018A (zh) * | 2012-10-17 | 2014-05-07 | 南京绿叶思科药业有限公司 | 一种卡巴他赛脂质体注射剂及其制备方法 |
| CA2903255C (en) * | 2013-03-13 | 2018-08-28 | Mallinckrodt Llc | Modified docetaxel liposome formulations |
| CN105209017A (zh) * | 2013-03-13 | 2015-12-30 | 马林克罗特有限公司 | 用于癌症疗法的脂质体顺铂组合物 |
| MX2019005185A (es) * | 2016-11-11 | 2019-07-01 | Univ Western Health Sciences | Metodos para tratar las carcinomas uroteliales del tracto superior. |
-
2017
- 2017-01-09 JP JP2018500936A patent/JP6697541B2/ja not_active Expired - Fee Related
- 2017-01-09 WO PCT/US2017/012720 patent/WO2017120586A1/en active Application Filing
- 2017-01-09 EP EP17736515.2A patent/EP3400072B1/en active Active
- 2017-01-09 CN CN201780002340.XA patent/CN108136217B/zh active Active
- 2017-01-09 SG SG11201805594PA patent/SG11201805594PA/en unknown
- 2017-01-09 CN CN202110437727.6A patent/CN113181118A/zh active Pending
- 2017-01-09 DK DK17736515.2T patent/DK3400072T3/da active
- 2017-01-09 MX MX2018008267A patent/MX2018008267A/es unknown
- 2017-01-09 CA CA3009809A patent/CA3009809A1/en active Pending
- 2017-01-09 US US16/066,836 patent/US11229602B2/en active Active
- 2017-01-09 PE PE2018001211A patent/PE20181445A1/es unknown
- 2017-01-09 CR CR20180388A patent/CR20180388A/es unknown
- 2017-01-09 MY MYPI2018001179A patent/MY198105A/en unknown
- 2017-01-09 KR KR1020187000357A patent/KR20180103039A/ko unknown
- 2017-01-09 BR BR112018013896A patent/BR112018013896A2/pt not_active IP Right Cessation
- 2017-01-09 EA EA201891575A patent/EA038653B1/ru unknown
- 2017-01-09 ES ES17736515T patent/ES2863659T3/es active Active
- 2017-01-09 AU AU2017205337A patent/AU2017205337B2/en active Active
-
2018
- 2018-06-28 IL IL260346A patent/IL260346B2/en unknown
- 2018-07-03 MX MX2020013858A patent/MX2020013858A/es unknown
- 2018-07-04 CL CL2018001838A patent/CL2018001838A1/es unknown
- 2018-07-06 PH PH12018501451A patent/PH12018501451A1/en unknown
- 2018-07-24 ZA ZA2018/04968A patent/ZA201804968B/en unknown
- 2018-07-25 CO CONC2018/0007674A patent/CO2018007674A2/es unknown
- 2018-11-09 HK HK18114340.8A patent/HK1255212A1/zh unknown
-
2019
- 2019-10-15 JP JP2019188572A patent/JP2020002181A/ja not_active Withdrawn
-
2021
- 2021-05-19 US US17/324,584 patent/US20210267896A1/en not_active Abandoned
-
2022
- 2022-09-12 JP JP2022144431A patent/JP2022168210A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891575A1 (ru) | Составы для лечения рака мочевого пузыря | |
| CO2022002685A2 (es) | Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos | |
| ECSP14012676A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
| AR110419A1 (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
| BR112018006922A2 (pt) | composições farmacêuticas estabilizantes de camptotecina | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201301266A8 (ru) | Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции | |
| BR112015032728A2 (pt) | formulação compósita em cápsula farmacêutica compreendendo tadalafil e tansulosina | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| CY1124893T1 (el) | Φαρμακευτικο μeιγμα μαροπιταντης | |
| EA201792286A1 (ru) | Способы лечения рака | |
| BR112014024033A8 (pt) | Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes | |
| DOP2017000069A (es) | Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores | |
| EA201590847A1 (ru) | Новые ингибиторы rock | |
| CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
| EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 | |
| Takenaga et al. | Potential new chemotherapy strategy for human ovarian carcinoma with a novel KSP inhibitor | |
| MX2018008196A (es) | Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional. | |
| AR108792A1 (es) | Composiciones que comprenden timolol |